Drug Profile
Research programme: chemokine antagonists - ICOS
Alternative Names: Chemokine antagonists research programme - ICOSLatest Information Update: 26 Mar 2009
Price :
$50
*
At a glance
- Originator ICOS Corporation
- Class Chemokines
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly and Company
- 28 Jun 2004 This programme is still in active development
- 02 Aug 2002 This programme is still in active development